The Experts below are selected from a list of 7767 Experts worldwide ranked by ideXlab platform
Michel Tod - One of the best experts on this subject based on the ideXlab platform.
-
fractionation of daily dose increases the predicted risk of severe sorafenib induced Hand Foot Syndrome hfs
Cancer Chemotherapy and Pharmacology, 2014Co-Authors: Emilie Henin, Benoit Blanchet, Gilles Freyer, Michel Vidal, François Goldwasser, Pascaline Boudourouquette, Audrey Thomasschoemann, Michel TodAbstract:Objectives The objective was to quantify the risk dynamics for the sorafenib-induced Hand–Foot Syndrome (HFS) and to explore by simulations the dose–toxicity relationships according to different dosing regimens.
-
Fractionation of daily dose increases the predicted risk of severe sorafenib‑induced Hand-Foot Syndrome (HFS)
Cancer chemotherapy and pharmacology, 2013Co-Authors: Emilie Henin, Benoit Blanchet, Pascaline Boudou-rouquette, Audrey Thomas-schoemann, Gilles Freyer, Michel Vidal, François Goldwasser, Michel TodAbstract:Objectives The objective was to quantify the risk dynamics for the sorafenib-induced Hand–Foot Syndrome (HFS) and to explore by simulations the dose–toxicity relationships according to different dosing regimens.
Muhammad Wasif Saif - One of the best experts on this subject based on the ideXlab platform.
-
Incidence and implications of chemotherapy related Hand-Foot Syndrome
Expert opinion on drug safety, 2016Co-Authors: V Nikolaou, K Syrigos, Muhammad Wasif SaifAbstract:Introduction: Hand-Foot Syndrome (HFS) is a well-established cutaneous adverse event of certain chemotherapeutic agents, mainly capecitabine, continuously infused 5-fluorouracil, docetaxel and pegy...
-
Topical henna ameliorated capecitabine-induced Hand-Foot Syndrome.
Cutaneous and ocular toxicology, 2013Co-Authors: Saher Ilyas, Komal Wasif, Muhammad Wasif SaifAbstract:AbstractBackground: Hand-Foot Syndrome (HFS) is the most frequently reported side effect of oral capecitabine therapy. In addition to treatment interruption and dose reduction, supportive treatments can help alleviate symptoms. Although its efficacy has not been proven in clinical studies, certain authors report on the use of prophylactic or therapeutic pyridoxine supplementation for the prevention of minimization to be useful in preventing worsening of HFS but are no substitute for dose modifications.Case report: We report a case of an interesting observation in a patient with pancreatic cancer receiving capecitabine whose HFS was improved with the use of “henna”.Discussion: Henna has been used for histories as a medicine, preservative, and cosmetic. Our case underlines the basis to further evaluate the anti-inflammatory, antipyretic, and analgesic effects of henna. We encourage other investigators to publish any similar cases or any other herbal or non-drug therapies. HFS is a common side effect of many...
-
capecitabine and Hand Foot Syndrome
Expert Opinion on Drug Safety, 2011Co-Authors: Muhammad Wasif SaifAbstract:Hand-Foot Syndrome (HFS), or palmar-plantar erythrodysesthesia, is a common side effect in patients taking long-term 5-fluorouracil treatment and is the most frequently reported side effect of oral capecitabine therapy (≥ 50% of patients). Although the pathogenesis of HFS is not fully understood, it may be due to damaged deep capillaries in the soles of the feet and palms of the Hands, leading to a COX inflammatory-type reaction, or related to enzymes involved in the metabolism of capecitabine, namely, thymidine phosphorylase and dihydropyrimidine dehydrogenase. Ethnic variations in the clinical manifestation of HFS warrant further attention, and an alternative system for grading HFS in non-white patients has been proposed. In addition to treatment interruption and dose reduction, supportive treatments can help alleviate symptoms. Because capecitabine is an oral therapy administered at home, it is crucial that patients understand the importance of complying with treatment, be aware of the possibility of HFS, and inform the doctor or nurse immediately if symptoms of HFS develop. Several cases of HFS are presented.
-
Capecitabine and Hand–Foot Syndrome
Expert opinion on drug safety, 2010Co-Authors: Muhammad Wasif SaifAbstract:Hand-Foot Syndrome (HFS), or palmar-plantar erythrodysesthesia, is a common side effect in patients taking long-term 5-fluorouracil treatment and is the most frequently reported side effect of oral capecitabine therapy (≥ 50% of patients). Although the pathogenesis of HFS is not fully understood, it may be due to damaged deep capillaries in the soles of the feet and palms of the Hands, leading to a COX inflammatory-type reaction, or related to enzymes involved in the metabolism of capecitabine, namely, thymidine phosphorylase and dihydropyrimidine dehydrogenase. Ethnic variations in the clinical manifestation of HFS warrant further attention, and an alternative system for grading HFS in non-white patients has been proposed. In addition to treatment interruption and dose reduction, supportive treatments can help alleviate symptoms. Because capecitabine is an oral therapy administered at home, it is crucial that patients understand the importance of complying with treatment, be aware of the possibility of HFS, and inform the doctor or nurse immediately if symptoms of HFS develop. Several cases of HFS are presented.
-
unilateral Hand Foot Syndrome an extraordinary side effect of capecitabine
Cutaneous and Ocular Toxicology, 2010Co-Authors: Umut Dişel, Özlem Gürkut, Huseyin Abali, Hakan Kaleagasi, Huseyin Mertsoylu, Ozgur Ozyilkan, Muhammad Wasif SaifAbstract:Background: Hand–Foot Syndrome (HFS), the most common toxicity of capecitabine, is characterized by tingling, numbness, pain, erythema, dryness, rash, swelling, increased pigmentation, and/or pruritus of the palmar and/or plantar surfaces of the Hands and/or feet. HFS is usually seen in both the Hands and the feet, with varying severity. We have previously published a case report of dihydropyrimidine dehydrogenase (DPD) deficiency that manifested a variant of HFS.Case report: We report the case of a 65-year-old Turkish Cypriot male patient with advanced gastric cancer who developed pain, numbness, and reddening in his left palm and left sole 10 days after the fourth cycle of capecitabine at a dose of 1,000 mg/m2/day twice daily (BID) on days 1 to 14 every 21 days. On physical examination, he had unilaterally erythematous changes and skin scaling on his left sole and palm consistent with grade II HFS. After stopping administration of capecitabine and supportive management, the HFS resolved in a week’s time...
Emilie Henin - One of the best experts on this subject based on the ideXlab platform.
-
fractionation of daily dose increases the predicted risk of severe sorafenib induced Hand Foot Syndrome hfs
Cancer Chemotherapy and Pharmacology, 2014Co-Authors: Emilie Henin, Benoit Blanchet, Gilles Freyer, Michel Vidal, François Goldwasser, Pascaline Boudourouquette, Audrey Thomasschoemann, Michel TodAbstract:Objectives The objective was to quantify the risk dynamics for the sorafenib-induced Hand–Foot Syndrome (HFS) and to explore by simulations the dose–toxicity relationships according to different dosing regimens.
-
Fractionation of daily dose increases the predicted risk of severe sorafenib‑induced Hand-Foot Syndrome (HFS)
Cancer chemotherapy and pharmacology, 2013Co-Authors: Emilie Henin, Benoit Blanchet, Pascaline Boudou-rouquette, Audrey Thomas-schoemann, Gilles Freyer, Michel Vidal, François Goldwasser, Michel TodAbstract:Objectives The objective was to quantify the risk dynamics for the sorafenib-induced Hand–Foot Syndrome (HFS) and to explore by simulations the dose–toxicity relationships according to different dosing regimens.
Gonullu Guzin - One of the best experts on this subject based on the ideXlab platform.
-
Topical henna for capecitabine induced Hand–Foot Syndrome
Investigational New Drugs, 2008Co-Authors: Idris Yucel, Gonullu GuzinAbstract:Capecitabine is a chemotherapeutic drug for use in cancers. Hand–Foot Syndrome (HFS) is side effect of capecitabine which can lead the cessation of the therapy or dose reduction. Henna ( Lawsonia inermis ) is a traditionally used plant of Middle-East that is applied on Hands and feet. Some of cancer patients in capecitabine treatment who developed HFS, we recommended to apply henna. In these patients, six patients were grade 3 HFS and four were grade 2 HFS. Complete response (CR) were seen in four of grade 3 HFS and all of grade 2; two grade 3 HFS improved to grade 1. So far, in the chemotherapy, there was no need of dose reduction and also no side effect of henna seen. Clinical improvement in these patients may relate to anti-inflammatory, antipyretic and analgesic effects of henna. Prospective studies are needed to show this therapeutic effect of henna.
-
Topical henna for capecitabine induced Hand-Foot Syndrome.
Investigational New Drugs, 2007Co-Authors: Idris Yucel, Gonullu GuzinAbstract:Capecitabine is a chemotherapeutic drug for use in cancers. Hand–Foot Syndrome (HFS) is side effect of capecitabine which can lead the cessation of the therapy or dose reduction. Henna (Lawsonia inermis) is a traditionally used plant of Middle-East that is applied on Hands and feet. Some of cancer patients in capecitabine treatment who developed HFS, we recommended to apply henna. In these patients, six patients were grade 3 HFS and four were grade 2 HFS. Complete response (CR) were seen in four of grade 3 HFS and all of grade 2; two grade 3 HFS improved to grade 1. So far, in the chemotherapy, there was no need of dose reduction and also no side effect of henna seen. Clinical improvement in these patients may relate to anti-inflammatory, antipyretic and analgesic effects of henna. Prospective studies are needed to show this therapeutic effect of henna.
Gilles Freyer - One of the best experts on this subject based on the ideXlab platform.
-
fractionation of daily dose increases the predicted risk of severe sorafenib induced Hand Foot Syndrome hfs
Cancer Chemotherapy and Pharmacology, 2014Co-Authors: Emilie Henin, Benoit Blanchet, Gilles Freyer, Michel Vidal, François Goldwasser, Pascaline Boudourouquette, Audrey Thomasschoemann, Michel TodAbstract:Objectives The objective was to quantify the risk dynamics for the sorafenib-induced Hand–Foot Syndrome (HFS) and to explore by simulations the dose–toxicity relationships according to different dosing regimens.
-
Fractionation of daily dose increases the predicted risk of severe sorafenib‑induced Hand-Foot Syndrome (HFS)
Cancer chemotherapy and pharmacology, 2013Co-Authors: Emilie Henin, Benoit Blanchet, Pascaline Boudou-rouquette, Audrey Thomas-schoemann, Gilles Freyer, Michel Vidal, François Goldwasser, Michel TodAbstract:Objectives The objective was to quantify the risk dynamics for the sorafenib-induced Hand–Foot Syndrome (HFS) and to explore by simulations the dose–toxicity relationships according to different dosing regimens.